As you transition from clinical to commercial biologic manufacturing, you are on a complex – yet exciting – journey as you are nearing the market and helping patients in need. Now is the time to make important decisions that will impact your commercial success.
How do you minimize risk and maximize process efficiency? Our Vice President Sébastien Ribault, Ph.D., and R-Pharm’s International Marketing Director Kira Ivanova will talk about our CDMO partnership and how the combination of our late-stage CDMO capabilities, single-use technology, and tailored guidance help prepare for production and, ultimately, accelerate and streamline R-Pharm’s commercial manufacturing process for olokizumab.
In this virtual event, you will discover more about:
Sébastien Ribault, Ph.D.
Vice President and Head of BioReliance® End-to-End Solutions
Sébastien joined MilliporeSigma in 2005 and is now vice president and head of BioReliance® end-to-end solutions based in Martillac, France, where he leads the CDMO branch dedicated to large molecules within the life science business. Sébastien also supports the development of new and innovative biomanufacturing technologies and solutions in collaboration with the company’s process development team.
VP, Own Brands, International Marketing
Kira graduated from the St. Petersburg State Chemical and Pharmaceutical Academy with a degree in biotechnology engineering. She began her career in the Sanofi Group and developed in various positions at Janssen, Johnson & Johnson. In 2015, Kira joined R-Pharm as a marketing manager and soon achieved the director position of the hepatology department. Since 2019, Kira has been leading the Olokizumab project by overseeing all matters related to the ex-Russia product launches. As of today, Kira has accumulated 14 years of experience in sales and marketing in the pharmaceutical industry.
To continue reading please sign in or create an account.Don't Have An Account?